654-2注射液在非小细胞肺癌动脉灌注化疗中的临床应用

Clinical study of 654-2 injection in bronchial artery infusion chemotherapy of non-small cell lung cancer

目的:观察654-2注射液在非小细胞肺癌动脉灌注化疗中的增效反应与不良反应。方法:76例中晚期NSCLC随机分为两组。对照组42例,经支气管动脉推注化疗药物(MMC、VDS、DDP);实验组34例,先经支气管动脉推注654-2注射液(10-20)mg,以后推注化疗药物;每月1次,连用3次为1疗程。结果:对照组有效率49.99%,实验组有效率61.76%,实验组疗效明显优于对照组(P=0.01)。不良反应率两组相似,无统计学差异(P>0.05)。结论:654-2注射液在中晚期非小细胞肺癌支气管动脉灌注化疗中能提高化疗疗效,不良反应轻微,具有一定的临床应用价值。

Objective ：To evaluate the response and adverse reaction of 654 -2 injection in bronchial arterial infusion （BAI） chemotherapy for non -small cell lung cancer（NSCLC）. Methods： All 76 patients with NSCLC in middle -later stage were divided randomly into control （42 cases） and treatment group （34 cases）. The patients in the control group were treated with BAI chemotherapy （MMC ＋ VDS ＋ DDP） only and in the treatment group were administered with BAI infusion 654 - 2 first and BAI chemotherapy （ MMC ＋ VDS ＋ DDP） later. The above therpy was given one time/month for 3 months. Results：The overall response rate was 49.99% in the control group and 61. 76% in the treatment group （P = 0.01 ）. There was no statistically significant difference between the two groups in the adverse effect（ P 〉 0.05 ）. Conclusion：The response of 654 -2 injection at metaphase and advanced NSCLC arterial infusion chemotherapy is obvious, and adverse effects is light,654 -2 injection is worthy to be further studied.